233 related articles for article (PubMed ID: 27136302)
1. Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase.
Neckles C; Pschibul A; Lai CT; Hirschbeck M; Kuper J; Davoodi S; Zou J; Liu N; Pan P; Shah S; Daryaee F; Bommineni GR; Lai C; Simmerling C; Kisker C; Tonge PJ
Biochemistry; 2016 May; 55(21):2992-3006. PubMed ID: 27136302
[TBL] [Abstract][Full Text] [Related]
2. Structure of the Yersinia pestis FabV enoyl-ACP reductase and its interaction with two 2-pyridone inhibitors.
Hirschbeck MW; Kuper J; Lu H; Liu N; Neckles C; Shah S; Wagner S; Sotriffer CA; Tonge PJ; Kisker C
Structure; 2012 Jan; 20(1):89-100. PubMed ID: 22244758
[TBL] [Abstract][Full Text] [Related]
3. Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.
Lu H; Tonge PJ
Biochemistry; 2010 Feb; 49(6):1281-9. PubMed ID: 20055482
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
5. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.
Massengo-Tiassé RP; Cronan JE
J Biol Chem; 2008 Jan; 283(3):1308-1316. PubMed ID: 18032386
[TBL] [Abstract][Full Text] [Related]
6. Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus.
Xu H; Sullivan TJ; Sekiguchi J; Kirikae T; Ojima I; Stratton CF; Mao W; Rock FL; Alley MR; Johnson F; Walker SG; Tonge PJ
Biochemistry; 2008 Apr; 47(14):4228-36. PubMed ID: 18335995
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
[TBL] [Abstract][Full Text] [Related]
8. Determination of the crystal structure and active residues of FabV, the enoyl-ACP reductase from Xanthomonas oryzae.
Li H; Zhang X; Bi L; He J; Jiang T
PLoS One; 2011; 6(10):e26743. PubMed ID: 22039545
[TBL] [Abstract][Full Text] [Related]
9. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
Kim YG; Seo JH; Kwak JH; Shin KJ
Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
[TBL] [Abstract][Full Text] [Related]
11. Effect of substrate binding loop mutations on the structure, kinetics, and inhibition of enoyl acyl carrier protein reductase from Plasmodium falciparum.
Maity K; Banerjee T; Prabakaran N; Surolia N; Surolia A; Suguna K
IUBMB Life; 2011 Jan; 63(1):30-41. PubMed ID: 21280175
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and Structural Basis of Triclosan Resistance in a Novel Enoyl-Acyl Carrier Protein Reductase.
Khan R; Zeb A; Roy N; Thapa Magar R; Kim HJ; Lee KW; Lee SW
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891603
[TBL] [Abstract][Full Text] [Related]
13. An Efficient and Economical Assay to Screen for Triclosan Binding to FabI.
Demissie RD; Kabre P; Tuntland ML; Fung LW
J Biomol Screen; 2016 Apr; 21(4):391-8. PubMed ID: 26538431
[TBL] [Abstract][Full Text] [Related]
14. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
[TBL] [Abstract][Full Text] [Related]
15. Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.
Neckles C; Eltschkner S; Cummings JE; Hirschbeck M; Daryaee F; Bommineni GR; Zhang Z; Spagnuolo L; Yu W; Davoodi S; Slayden RA; Kisker C; Tonge PJ
Biochemistry; 2017 Apr; 56(13):1865-1878. PubMed ID: 28225601
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase.
Tipparaju SK; Joyasawal S; Forrester S; Mulhearn DC; Pegan S; Johnson ME; Mesecar AD; Kozikowski AP
Bioorg Med Chem Lett; 2008 Jun; 18(12):3565-9. PubMed ID: 18499454
[TBL] [Abstract][Full Text] [Related]
17. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.
Kitagawa H; Kumura K; Takahata S; Iida M; Atsumi K
Bioorg Med Chem; 2007 Jan; 15(2):1106-16. PubMed ID: 17095231
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and Structural Insights Concerning Triclosan Resistance in a Novel YX
Khan R; Zeb A; Choi K; Lee G; Lee KW; Lee SW
Sci Rep; 2019 Oct; 9(1):15401. PubMed ID: 31659200
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.
Tipparaju SK; Mulhearn DC; Klein GM; Chen Y; Tapadar S; Bishop MH; Yang S; Chen J; Ghassemi M; Santarsiero BD; Cook JL; Johlfs M; Mesecar AD; Johnson ME; Kozikowski AP
ChemMedChem; 2008 Aug; 3(8):1250-68. PubMed ID: 18663709
[TBL] [Abstract][Full Text] [Related]
20. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
Zhu L; Lin J; Ma J; Cronan JE; Wang H
Antimicrob Agents Chemother; 2010 Feb; 54(2):689-98. PubMed ID: 19933806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
